New structural templates for clinically validated and novel targets in antimicrobial drug research and development

Current Topics in Microbiology and Immunology

Volumn 398, Issue , 2016, Pages 365-417

  Klahn, Philipp ^a   Brönstrup, Mark ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; BLEOMYCIN; CARBENICILLIN; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; COUMAMYCIN DERIVATIVE; DNA TOPOISOMERASE; DORIPENEM; ERTAPENEM; GEMIFLOXACIN; GEPOTIDACIN; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; MEROPENEM; METICILLIN; NOCARDICIN A; NORFLOXACIN; OXACILLIN; SULFADIAZINE; SULFAMETHOXAZOLE; TABTOXIN; TEICOPLANIN; TELAVANCIN; TIGEMONAM; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL OUTER MEMBRANE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BINDING SITE; DRUG DEVELOPMENT; DRUG PROTEIN BINDING; DRUG STRUCTURE; ELECTRON TRANSPORT; GONORRHEA; GRAM POSITIVE BACTERIUM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RESPIRATORY TRACT INFECTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUBERCULOSIS; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; MOLECULAR STRUCTURE;

EID: 85007304703     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2016_501     Document Type: Article

References (333)

1. Aguilaniu H, Durieux J, Dillin A (2005) Metabolism, ubiquinone synthesis, and longevity. Genes Dev 19:2399-2406. doi:10.1101/gad.1366505.
2. Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565-1574. doi:10.1021/bi5000564.
3. Alm RA, Lahiri SD, Kutschke A et al (2015) Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59:1478-1486. doi:10.1128/AAC.04456-14.
4. Amaral L, Martins A, Spengler G, Molnar J (2014) Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol 4:Article168. doi:10.3389/fphar.2013.00168.
5. Anderson VE, Osheroff N (2001) Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7:337-353. doi:10.2174/1381612013398013.
6. Anderson RJ, Groundwater PW, Todd A, Worsley AJ (2012) Antibacterial agents: chemistry, mode of action, mechanisms of resistance and clinical applications. Wiley, New York.
7. Argiriadi MA, Goedken ER, Bruck I, et al (2006) Crystal structure of a DNA polymerase sliding clamp from a Gram-positive bacterium. BMC Struct Biol 6:2. doi:10.1186/1472-6807-6-2.
8. Askoura M, Mottawea W, Abujamel T, Taher I (2011) Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med 6:1-8. doi:10.3402/ljm.v6i0.5870.
9. Atilano ML, Pereira PM, Yates J et al (2010) Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus. Proc Natl Acad Sci USA 107:1899118996. doi:10.1073/pnas.1004304107.
10. Baltrus DA (2013) Exploring the costs of horizontal gene transfer. Trends Ecol Evol 28:489-495. doi:10.1016/j.tree.2013.04.002.
11. Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8:557-563. doi:10.1016/j.coph.2008.04.008.
12. Basarab GS, Manchester JI, Bist S et al (2013) Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J Med Chem 56:8712-8735. doi:10.1021/jm401208b.
13. Basarab GS, Kern GH, McNulty J et al (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep 5:11827. doi:10.1038/srep11827.
14. Bates AD, Maxwell A (2007) Energy coupling type II topoisomerase why do they hydrolyze ATP? Biochemistry 46:7929-7941. doi:10.1021/bi700789g.
15. Bauer A, Brönstrup M (2014) Industrial natural product chemistry for drug discovery and development. Nat Prod Rep 31:35-60. doi:10.1039/c3np70058e.
16. Bauer R, Dicks LMT (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol 101:201-216. doi:10.1016/j.ijfoodmicro.2004.11.007.
17. Baumann S, Herrmann J, Raju R et al (2014) Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew Chem Int Ed 53:14605-14609. doi:10.1002/anie.201409964.
18. Bax BD, Chan PF, Eggleston DS et al (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. doi:10.1038/nature09197.
19. Bénazet et al (1966) Antibiotics-advances in research, production and clinical use. In: Herold M, Gabriel Z (eds) Proceedings of the congress on antibiotics held in Prague, 15-19 June, 1964. Butterworths, London, pp 262-264.
20. Bengtsson B, Greko C (2014) Antibiotic resistance-consequences for animal health, welfare, and food production. Ups J Med Sci 119:96-102. doi:10.3109/03009734.2014.901445.
21. Bérdy J (2012) Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot 65:441. doi:10.1038/ja.2012.54.
22. Berleman J, Auer M (2013) The role of bacterial outer membrane vesicles for intraand interspecies delivery. Environ Microbiol 15:347-354. doi:10.1111/1462-2920.12048.
23. Bierbaum G, Sahl HG (1985) Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch Microbiol 141:249-254. doi:10.1007/BF00408067.
24. Birch RG, Patil SS (1987a) Correlation between albicidin production and chlorosis induction by Xanthomonas albilineans, the sugarcane leaf scald pathogen. Physiol Mol Plant Pathol 30:199206. doi:10.1016/0885-5765(87)90033-6.
25. Birch RG, Patil SS (1987b) Evidence that an albicidin-like phytotoxin induces chlorosis in sugarcane leaf scald disease by blocking plastid DNA replication. Physiol Mol Plant Pathol 30:207-214. doi:10.1016/0885-5765(87)90034-8.
26. Biswas S, Brunel J-M, Dubus J-C et al (2012) Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917-934. doi:10.1586/eri.12.78.
27. Blair JMA, Richmond GE, Piddock LJV (2014) Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol 9:1165-1177. doi:10.2217/fmb.14.66.
28. Bloom LB (2009) Loaing clamps for DNA replication and repair. DNA Repair 8:570-578. doi:10.1016/j.dnarep.2008.12.014.Loading.
29. Blunt JW, Copp BR, Munro MHG et al (2011) Marine natural products. Nat Prod Rep 28:196268. doi:10.1039/c005001f.
30. Boneca IG, Chiosis G (2003) Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opin Ther Targets 7:311-328. doi:10.1517/14728222.7.3.311.
31. Bouchaudon J (1964) Nouveau cyclopeptide, sa préparation et les médicaments qui le contiennent.
32. Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. doi:10.1086/595011.
33. Boucher HW, Talbot GH, Benjamin DK et al (2013) 10 x ‘20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious diseases society of America. Clin Infect Dis 56:1685-1694. doi:10.1093/cid/cit152.
34. Bozdogan B, Appelbaum PC (2004) Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23:113-119. doi:10.1016/j.ijantimicag.2003.11.003.
35. Breu F, Guggenbichler S, Wollmann J (2001) Human as the world’s greatest evolutionary force. Science 293:1786-1790.
36. Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5:321332. doi:10.1038/nrd2004.
37. Brötz H, Josten M, Wiedemann I et al (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30:317-327. doi:10.1046/j.1365-2958.1998.01065.x.
38. Brötz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr Opin Pharmacol 8:564-573. doi:10.1016/j.coph.2008.06.008.
39. Brown S, Xia G, Luhachack LG et al (2012) Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids. Proc Natl Acad Sci USA 109:18909-18914. doi:10.1073/pnas.1209126109.
40. Brown S, Santa Maria JP, Walker S (2013) Wall teichoic acids of gram-positive bacteria. Annu Rev Microbiol 67:313-336. doi:10.1146/annurev-micro-092412-155620.
41. Brown DG, Lister T, May-Dracka TL (2014) New natural products as new leads for antibacterial drug discovery. Bioorg Med Chem Lett 24:413-418. doi:10.1016/j.bmcl.2013.12.059.
42. Brown L, Wolf JM, Prados-Rosales R, Casadevall A (2015) Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol 13:620-630. doi:10.1038/nrmicro3480.
43. Bunting KA, Roe SM, Pearl LH (2003) Structural basis for recruitment of translesion DNA polymerase Pol IV/DinB to the b-clamp. EMBO J 22:5883-5892. doi:10.1093/emboj/cdg568.
44. Burnouf DY, Olieric V, Wagner J et al (2004) Structural and biochemical analysis of sliding clamp/ligand interactions suggest a competition between replicative and translesion DNA polymerases. J Mol Biol 335:1187-1197. doi:10.1016/j.jmb.2003.11.049.
45. Bush K (2010) Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 14:224. doi:10.1186/cc8892.
46. Bush K (2015) Investigational agents for the treatment of Gram-negative bacterial infections: a reality check. ACS Infect Dis 1:509-511. doi:10.1021/acsinfecdis.5b00100.
47. Butler EK, Davis RM, Bari V et al (2013a) Structure-function analysis of MurJ reveals a solvent-exposed cavity containing residues essential for peptidoglycan biogenesis in Escherichia coli. J Bacteriol 195:4639-4649. doi:10.1128/JB.00731-13.
48. Butler MS, Blaskovich MA, Cooper MA (2013b) Antibiotics in the clinical pipeline in 2013. J Antibiot 66:571-591. doi:10.1038/ja.2013.86.
49. Butler MS, Robertson AAB, Cooper MA (2014) Natural product and natural product derived drugs in clinical trials. Nat Prod Rep 31:1612-1661. doi:10.1039/c4np00064a.
50. Campbell J, Singh AK, Swoboda JG et al (2012) An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in Staphylococcus aureus. Antimicrob Agents Chemother 56:1810-1820. doi:10.1128/AAC.05938-11.
51. Carattoli A (2013) Plasmids and the spread of resistance. Int J Med Microbiol 303:298-304. doi:10.1016/j.ijmm.2013.02.001.
52. Casacuberta E, Gonzalez J (2013) The impact of transposable elements in environmental adaptation. Mol Ecol 22:1503-1517. doi:10.1111/mec.12170.
53. Cervellati R, Greco E (2016) In vitro antioxidant activity of ubiquinone and ubiquinol, compared to vitamin E. Helv Chim Acta 99:41-45. doi:10.1002/hlca.201500124.
54. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413. doi:10.1161/01.RES.0000255691.76142.4a.
55. Chan WC, Bycroft BW, Lian L-Y, Roberts GCK (1989) Isolation and characterisation of two degradation products derived from the peptide antibiotic nisin. FEBS Lett 252:29-36. doi:10.1016/0014-5793(89)80884-1.
56. Chen Q, Duan F, Li X et al (2014) Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase i. J Med Chem 57:3707-3714. doi:10.1021/jm401685f.
57. Cho WK, Jergic S, Kim D et al (2014) Loading dynamics of a sliding DNA clamp. Angew Chem Int Ed 53:6768-6771. doi:10.1002/anie.201403063.
58. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260. doi:10.1128/MMBR.65.2.232.
59. Chopra S, Matsuyama K, Tran T et al (2012) Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother 67:415-421. doi:10.1093/jac/dkr449.
60. Chung BC, Zhao J, Gillespie RA et al (2013) Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis. Science 341:1012-1016. doi:10.1126/science.1236501.
61. Clardy J, Fischbach MA, Walsh CT (2006) New antibiotics from bacterial natural products. Nat Biotechnol 24:1541-1550. doi:10.1038/nbt1266.
62. Cleveland J, Montville TJ, Nes IF, Chikindas ML (2001) Bacteriocins: Safe, natural antimicrobials for food preservation. Int J Food Microbiol 71:1-20. doi:10.1016/S0168-1605(01)00560-8.
63. Coates AR, Halls G, Hu Y (2011) Novel classes of antibiotics or more of the same? Br J Pharmacol 163:184-194. doi:10.1111/j.1476-5381.2011.01250.x.
64. Cociancich S, Pesic A, Petras D et al (2015) The gyrase inhibitor albicidin consists of p-aminobenzoic acids and cyanoalanine. Nat Chem Biol 11:195-197. doi:10.1038/nchembio.1734.
65. Cohen GN (2011) Microbial biochemistry, 2nd edn. Springer, Heidelberg.
66. Cole ST, Riccardi G (2011) New tuberculosis drugs on the horizon. Curr Opin Microbiol 14:570576. doi:10.1016/j.mib.2011.07.022.
67. Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl Microbiol Biotechnol 92:479-497. doi:10.1007/s00253-011-3557-z.
68. Connor EE (1998) Sulfonamide antibiotics. Prim Care Update Ob Gyns 5:32-35.
69. Costenaro L, Grossmann JG, Ebel C, Maxwell A (2007) Modular structure of the full-length DNA gyrase B subunit revealed by small-angle X-ray scattering. Structure 15:329-339. doi:10.1016/j.str.2007.01.013.
70. Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta-Gen Subj 1830:3670-3695. doi:10.1016/j.bbagen.2013.02.008.
71. Czaplewski L, Bax R, Clokie M et al (2016) Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:239-251. doi:10.1016/S1473-3099(15)00466-1.
72. D’Costa VM, King CE, Kalan L et al (2011) Antibiotic resistance is ancient. Nature 477:457-461. doi:10.1038/nature10388.
73. D’Elia MA, Millar KE, Beveridge TJ, Brown ED (2006a) Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis. J Bacteriol 188:8313-8316. doi:10.1128/JB.01336-06.
74. D’Elia MA, Pereira MP, Chung YS et al (2006b) Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J Bacteriol 188:4183-4189. doi:10.1128/JB.00197-06.
75. D’Elia MA, Henderson JA, Beveridge TJ et al (2009a) The N-acetylmannosamine transferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 191:4030-4034. doi:10.1128/JB.00611-08.
76. D’Elia MA, Pereira MP, Brown ED (2009b) Are essential genes really essential? Trends Microbiol 17:433-438. doi:10.1016/j.tim.2009.08.005.
77. Dalrymple BP, Kongsuwan K, Wijffels G et al (2001) A universal protein-protein interaction motif in the eubacterial DNA replication and repair systems. Proc Natl Acad Sci U S A 98:11627-11632. doi:10.1073/pnas.191384398.
78. Davies J (2006) Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 17:287-290.
79. Davis BD (1987) Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51:341350 doi:0146-0749/87/030341-1002.00/0.
80. de Kruijff B, van Dam V, Breukink E (2008) Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics. Prostaglandins Leukot Essent Fat Acids 79:117-121. doi:10.1016/j.plefa.2008.09.020.
81. Debnath J, Siricilla S, Wan B et al (2012) Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem 55:3739-3755. doi:10.1021/jm201608g.
82. Dhiman RK, Mahapatra S, Slayden RA et al (2009) Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72:85-97. doi:10.1111/j.1365-2958.2009.06625.x.
83. Diez J, Martinez JP, Mestres J et al (2012) Myxobacteria: natural pharmaceutical factories. Microb Cell Fact 11:52-54. doi:10.1186/1475-2859-11-52.
84. Donnell MO, Langston L, Stillman B et al (2013) Principles and concepts of DNA replication in bacteria, archea, and eukarya. Cold Spring Harb Perspect Biol 5:a010180. doi:10.1101/cshperspect.a010108.
85. Doroghazi JR, Albright JC, Goering AW et al (2014) A roadmap for natural product discovery based on large-scale genomics and metabolomics. Nat Chem Biol 10:963-968. doi:10.1038/nchembio.1659.
86. Dougherty TJ, Nayar A, Newman JV et al (2014) NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with Gram-negative antibacterial activity and in vivo efficacy. Antimicrob Agents Chemother. doi:10.1128/aac.02778-13.
87. Dubée V, Chau F, Arthur M et al (2011) The in vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalis. Antimicrob Agents Chemother 55:910-912. doi:10.1128/AAC.01230-10.
88. Edwards DI (1993) Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9-20. doi:10.1093/jac/31.1.9.
89. Ehmann DE, Lahiri SD (2014) Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Curr Opin Pharmacol 18:76-83. doi:10.1016/j.coph.2014.09.007.
90. Eichberg MJ (2015) Public funding of clinical-stage antibiotic development in the United States and European Union. Heal Secur 13:156-165. doi:10.1089/hs.2014.0081.
91. Elshahawi SI, Shaaban KA, Kharel MK, Thorson JS (2015) A comprehensive review of glycosylated bacterial natural products. Chem Soc Rev 44:7591-7697. doi:10.1039/C4CS00426D.
92. Epand RM, Walker C, Epand RF, Magarvey NA (2016) Molecular mechanisms of membrane targeting antibiotics. BBA Biomembranes 1858:980-987. doi:10.1016/j.bbamem.2015.10.018.
93. European Centre for Disease Prevention and Control (2012) Annual report of the European antimicrobial resistance surveilance network (EARS-Net). ECDC, Stockholm.
94. Farha MA, Leung A, Sewell EW et al (2013) Inhibition of WTA synthesis blocks the cooperative action of pbps and sensitizes MRSA to b-lactams. ACS Chem Biol 8:226-233. doi:10.1021/cb300413m.
95. Finn J (2013) Evaluation of WO2012177707 and WO2012097269: Vertex’s phosphate prodrugs of gyrase and topoisomerase antibacterial agents. Expert Opin Ther Pat 23:1233-1237. doi:10.1517/13543776.2013.820707.
96. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science 325:1089-1093. doi:10.1126/science.1176667.
97. Floss HG, Yu T-W (2005) Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 105:621-632. doi:10.1021/cr030112j.
98. Forsberg KJ, Reyes A, Wang B et al (2012) The shared antibiotic resistome of soil bacteria and human pathogens. Science 337:1107-1111. doi:10.1126/science.1220761.
99. Frankel RB, Kalmijn AJ, Amann R et al (2006) Sampling the antibiotic resistome. Science 311:374-378. doi:10.1126/science.1120800.
100. Fujimoto N, Kosaka T, Yam M (2012) Menaquinone as well as ubiquinone as a crucial component in the Escherichia coli respiratory chain. In: Ekinci D (ed) Chemical biology, pp 187-208.
101. Georgescu RE, Kim SS, Yurieva O et al (2008a) Structure of a sliding clamp on DNA. Cell 132:43-54. doi:10.1016/j.cell.2007.11.045.
102. Georgescu RE, Yurieva O, Kim S-S et al (2008b) Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp. Proc Natl Acad Sci USA 105:11116-11121. doi:10.1073/pnas.0804754105.
103. Gerth K, Pradella S, Perlova O et al (2003) Myxobacteria: Proficient producers of novel natural products with various biological activities-past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol 106:233-253. doi:10.1016/j.jbiotec.2003.07.015.
104. Gibbons S (2004) Anti-staphylococcal plant natural products. Nat Prod Rep 21:263-277. doi:10.1039/b212695h.
105. Giguère S (2013) Lincosamides, pleuromutilins, and streptogramins. Antimicrob Ther Vet Med 199-210. doi:10.1016/0007-1935(89)90107-3.
106. Gilbert GL (2015) Knowing when to stop antibiotic therapy. Med J Aust 202:121-123. doi:10.5694/mja14.01201.
107. Gillings MR (2013) Evolutionary consequences of antibiotic use for the resistome, mobilome, and microbial pangenome. Front Microbiol 4:1-10. doi:10.3389/fmicb.2013.00004.
108. Godtfredsen WO, Jahnsen S, Lorck H et al (1962) Fusidic acid: a new antibiotic. Nature 193:987.
109. Górska A, Sloderbach A, Marszałł MP (2014) Siderophore-drug complexes: Potential medicinal applications of the “Trojan horse” strategy. Trends Pharmacol Sci 1-8. doi:10.1016/j.tips.2014.06.007.
110. Gubaev A, Klostermeier D (2014) Reprint of "the mechanism of negative DNA supercoiling: a cascade of DNA-induced conformational changes prepares gyrase for strand passage". DNA Repair (Amst) 20:130-141. doi:10.1016/j.dnarep.2014.06.006.
111. Gui W-J, Lin S-Q, Chen Y-Y et al (2011) Crystal structure of DNA polymerase III b sliding clamp from Mycobacterium tuberculosis. Biochem Biophys Res Commun 405:272-277. doi:10.1016/j.bbrc.2011.01.027.
112. Hamamoto H, Urai M, Ishii K et al (2014) Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat Chem Biol 11:127-133. doi:10.1038/nchembio.1710.
113. Hammes WP, Neuhaus FC (1974) On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari. Antimicrob Agents Chemother 6:722-728. doi:10.1128/AAC.6.6.722.
114. Harrison E, Brockhurst MA (2012) Plasmid-mediated horizontal gene transfer is a coevolutionary process. Trends Microbiol 20:262-267. doi:10.1016/j.tim.2012.04.003.
115. Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14:111-129. doi:10.1038/nrd4510.
116. Hashimi SM, Wall MK, Smith AB et al (2007) The phytotoxin albicidin is a novel inhibitor of DNA gyrase. Antimicrob Agents Chemother 51:181-187. doi:10.1128/AAC.00918-06.
117. Hawkey PM, Livermore DM (2012) Carbapenem antibiotics for serious infections. BMJ 344:1-7. doi:10.1136/bmj.e3236.
118. Hawser S, Lociuro S, Islam K (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71:941-948. doi:10.1016/j.bcp.2005.10.052.
119. Hecker SJ, Reddy KR, Totrov M et al (2015) Discovery of a cyclic boronic acid b-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682-3692. doi:10.1021/acs.jmedchem.5b00127.
120. Heide L (2014) New aminocoumarin antibiotics as gyrase inhibitors. Int J Med Microbiol 304:31-36. doi:10.1016/j.ijmm.2013.08.013.
121. Henry RJ (1943) The mode of action of sulfonamides. Bacteriol Rev 7:175-262. doi:10.1128/AEM.02766-10.
122. Herrmann J, Lukežič T, Kling A, et al (2016) Strategies for the discovery and development of new antibiotics from natural products: three case studies. Curr Top Microbiol Immunol.
123. Hesterkamp T (2016) Antibiotics clinical development and pipeline. Curr Top Microbiol Immunol. doi:10.1007/82_2015_451.
124. Hiratsuka T, Furihata K, Ishikawa J et al (2008) An alternative menaquinone biosynthetic pathway operating in microorganisms. Science 321:1670-1673. doi:10.1126/science.1160446.
125. Hirsch EB, Ledesma KR, Chang KT et al (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753-3757. doi:10.1128/AAC.05927-11.
126. Holzgrabe U (2015) New griselimycins for treatment of tuberculosis. Chem Biol 22:981-982. doi:10.1016/j.chembiol.2015.08.002.
127. Hooper DC, Wolfson JS, McHugh GL et al (1982) Effects of novobiocin, coumermycin-a1, clorobiocin, and their analogs on Escherichia-coli Dna gyrase and bacterial-growth. Antimicrob Agents Chemother 22:662-671.
128. Hsu S-TD, Breukink E, Tischenko E et al (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11:963967. doi:10.1038/nsmb830.
129. Huang G, Zhang L, Birch RG (2001) A multifunctional polyketide-peptide synthetase essential for albicidin biosynthesis in Xanthomonas albilineans. Microbiology 147:631-642.
130. Jacobsson S, Golparian D, Alm RA et al (2014) High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585-5588. doi:10.1128/AAC.03090-14.
131. Jacoby GA (2005) Mechanisms of bacterial resistance to quinolones. 41:S120-S126.
132. Jad YE, Acosta GA, Naicker T et al (2015) Synthesis and biological evaluation of a teixobactin analogue. Org Lett 17:6182-6185. doi:10.1021/acs.orglett.5b03176.
133. Ji C, Juárez-Hernández RE, Miller MJ (2012) Exploiting bacterial iron acquisition: siderophore conjugates. Future Med Chem 4:297-313. doi:10.4155/fmc.11.191.
134. Jia Z, O’Mara ML, Zuegg J et al (2013) Vancomycin: ligand recognition, dimerization and super-complex formation. FEBS J 280:1294-1307. doi:10.1111/febs.12121.
135. Johnston CW, Magarvey NA (2015) Natural products: untwisting the antibiotic’ome. Nat Chem Biol 11:177-178. doi:10.1038/nchembio.1757.
136. Johnston CW, Skinnider MA, Dejong CA et al (2016) Assembly and clustering of natural antibiotics guides target identification. Nat Chem Biol 12:233-239. doi:10.1038/nchembio.2018.
137. Johnstone TC, Nolan EM (2015) Beyond iron: non-classical biological functions of bacterial siderophores. Dalton Trans 44:6320-6339. doi:10.1039/c4dt03559c.
138. Jolles G (1971) New cyclopeptides, GB Patent 1,252,553.
139. Kahne D, Leimkuhler C, Lu W, Walsh C (2005) Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105:425-448. doi:10.1021/cr030103a.
140. Kåhrström CT (2015) Antimicrobials: a new drug for resistant bugs. Nat Rev Microbiol 13:126-127. doi:10.1038/nrmicro3429.
141. Kale MG, Raichurkar A, Shahul Hameed P et al (2013) Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA gyrase B. J Med Chem 56:8834-8848. doi:10.1021/jm401268f.
142. Kale RR, Kale MG, Waterson D et al (2014) Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. Bioorg Med Chem Lett 24:870-879. doi:10.1016/j.bmcl.2013.12.080.
143. Kalman D, Barriere S (1990) Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J 17:203-215.
144. Kannan K, Mankin AS (2011) Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann N Y Acad Sci 1241:33-47. doi:10.1111/j.1749-6632.2011.06315.x.
145. Kawamukai M (2002) Biosynthesis, Bioproduction and Novel Roles of Ubiquinone. J Biosci Bioeng 94:511-517.
146. Keller S, Schadt HS, Ortel I, Süssmuth RD (2007) Action of atrop-abyssomicin C as an inhibitor of 4-amino-4-deoxychorismate synthase PabB. Angew Chem Int Ed 46:8284-8286. doi:10.1002/anie.200701836.
147. Kern G, Palmer T, Ehmann DE, et al (2015) Inhibition of Neisseria gonorrhoeae type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. J Biol Chem M115.663534. doi:10.1074/jbc.M115.663534.
148. Kirst HA (2013) Developing new antibacterials through natural product research. Expert Opin Drug Discov 8:479-493. doi:10.1517/17460441.2013.779666.
149. Kjelstrup S, Hansen PMP, Thomsen LE et al (2013) Cyclic Peptide Inhibitors of the b-Sliding Clamp in Staphylococcus aureus. PLoS ONE. doi:10.1371/journal.pone.0072273.
150. Kling A, Lukat P, Almeida DV et al (2015) Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348:1106-1112. doi:10.1126/science.aaa4690.
151. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206-220. doi:10.1038/nrd1657.
152. Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8:423-435. doi:10.1038/nrmicro2333.
153. Kotra LP, Haddad J, Mobashery S (2000) Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44:3249-3256. doi:10.1128/AAC.44.12.3249-3256.2000.Updated.
154. Kramer NE, Smid EJ, Kok J et al (2004) Resistance of Gram-positive bacteria to nisin is not determined by Lipid II levels. FEMS Microbiol Lett 239:157-161. doi:10.1016/j.femsle.2004.08.033.
155. Kretz J, Kerwat D, Schubert V et al (2015) Total synthesis of albicidin: A lead structure from xanthomonas albilineans for potent antibacterial gyrase inhibitors. Angew Chem Int Ed 54:1969-1973. doi:10.1002/anie.201409584.
156. Kuipers OP, Rollema HS, de Vos WM, Siezen RJ (1993) Biosynthesis and secretion of a precursor of nisin Z by Lactococcus lactis, directed by the leader peptide of the homologous lantibiotic subtilin from Bacillus subtilis. FEBS Lett 330:23-27. doi:10.1016/0014-5793(93)80911-D.
157. Kurosu M, Begari E (2010) Vitamin K2 in electron transport system: are enzymes involved in vitamin K2 biosynthesis promising drug targets? Molecules 15:1531-1553. doi:10.3390/molecules15031531.
158. Kurosu M, Narayanasamy P, Biswas K et al (2007) Discovery of 1,4-didydroxy-2-naphthoate prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens. J Med Chem 50:3973-3975. doi:10.1021/jm070638m.
159. Lapierre P, Gogarten JP (2009) Estimating the size of the bacterial pan-genome. Trends Genet 25:107-110. doi:10.1016/j.tig.2008.12.004.
160. Lapuebla A, Abdallah M, Olafisoye O et al (2015a) Activity of imipenem with relebactam against gram-negative pathogens from New York City: Table 1. Antimicrob Agents Chemother 59:5029-5031. doi:10.1128/AAC.00830-15.
161. Lapuebla A, Abdallah M, Olafisoye O, et al (2015b) Activity of meropenem combined with RPX7009, a novel b-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:AAC.00843-15. doi:10.1128/AAC.00843-15.
162. Lazarevic V, Karamata D (1995) The tagGH operon of Bacillus subtilis 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. Mol Microbiol 16:345-355. doi:10.1111/j.1365-2958.1995.tb02306.x.
163. Lee K, Campbell J, Swoboda JG et al (2010) Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg Med Chem Lett 20:1767-1770. doi:10.1016/j.bmcl.2010.01.036.
164. Lee SH, Wang H, Labroli M, et al (2016a) TarO-specific inhibitors of wall teichoic acid biosynthesis restore b -lactam efficacy against methicillin-resistant staphylococci. Sci Transl Med 8:329ra32. doi:10.1126/scitranslmed.aad7364.
165. Lee W, Schaefer K, Qiao Y et al (2016b) The mechanism of action of lysobactin. J Am Chem Soc 138:100-103. doi:10.1021/jacs.5b11807.
166. Leski TA, Tomasz A (2005) Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus. J Bacteriol 2:1815-1824. doi:10.1128/JB.187.5.1815.
167. Leu FP, Hingorani MM, Turner J, O’Donnell M (2000) The d subunit of DNA polymerase III holoenzyme serves as a sliding clamp unloader in Escherichia coli. J Biol Chem 275:34609-34618. doi:10.1074/jbc.M005495200.
168. Lewis K (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov 12:371-387. doi:10.1038/nrd3975.
169. Lim D, Strynadka NCJ (2002) Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 9:870-876. doi:10.1038/nsb858.
170. Lin AH, Murray RW, Vidmar TJ, Marotti KR (1997) The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 41:2127-2131.
171. Ling LL, Schneider T, Peoples AJ et al (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455-459. doi:10.1038/nature14098.
172. Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28:352-364. doi:10.1086/515104.
173. Littmann J, Buyx A, Cars O (2015) Antibiotic resistance: An ethical challenge. Int J Antimicrob Agents 46:359-361. doi:10.1016/j.ijantimicag.2015.06.010.
174. Liu LF, Liu CC, Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19:697-707. doi:10.1016/S0092-8674(80)80046-8.
175. Livermore DM, Warner M, Mushtaq S (2013) Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286-2290. doi:10.1093/jac/dkt178.
176. Livermore DM, Mushtaq S, Warner M, Woodford N (2015) Activity of OP0595/b-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing b-lactamases. J Antimicrob Chemother 70:3032-3041. doi:10.1093/jac/dkv239.
177. Lowther GE (1979) The united states food and drug administration and the practice of optometry. J Am Optom Assoc 50:579-582.
178. Lu X, Zhou R, Sharma I et al (2012) Stable analogues of OSB-AMP: potent Inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. ChemBioChem 13:129-136. doi:10.1002/cbic.201100585.
179. Maki H, Yamaguchi T, Murakami K (1994) Cloning and characterization of a gene affecting the methicillin resistance level and the autolysis rate in Staphylococcus aureus. J Bacteriol 176:4993-5000.
180. Maren TH (1976) Relatons between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 16:309-327. doi:10.1146/annurev.pa.16.040176.001521.
181. Martin NI, Breukink E (2007) Expanding role of lipid II as a target for lantibiotics. Future Microbiol 2:513-525. doi:10.2217/17460913.2.5.513.
182. Mast Y, Wohlleben W (2014) International Journal of Medical Microbiology Streptogramins Two are better than one ! 304:44-50.
183. Maxwell A (1993) The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 9:681-686. doi:10.1111/j.1365-2958.1993.tb01728.x.
184. Maxwell A, Lawson DM (2003) The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 3:283-303. doi:10.2174/1568026033452500.
185. Mayer C, Janin YL (2014) Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem Rev 114:2313-2342.
186. Mccomas CC, Mccomas CC, Crowley BM et al (2003) Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions. J Am Chem Soc 125:9314-9315.
187. Medini D, Donati C, Tettelin H et al (2005) The microbial pan-genome. Curr Opin Genet Dev 15:589-594. doi:10.1016/j.gde.2005.09.006.
188. Meeske AJ, Sham L-T, Kimsey H et al (2015) MurJ and a novel lipid II flippase are required for cell wall biogenesis in Bacillus subtilis. Proc Natl Acad Sci U S A 112:6437-6442. doi:10.1073/pnas.1504967112.
189. Meredith TC, Swoboda JG, Walker S (2008) Late-stage polyribitol phosphate wall teichoic acid biosynthesis in Staphylococcus aureus. J Bacteriol 190:3046-3056. doi:10.1128/JB.01880-07.
190. Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15:e732-e739. doi:10.1016/j.ijid.2011.07.007.
191. Miles TJ, Hennessy AJ, Bax B et al (2013) Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett 23:5437-5441. doi:10.1016/j.bmcl.2013.07.013.
192. Miller EL (2002) The penicillins: a review and update. J Midwifery Women’s Heal 47:426-434. doi:10.1016/S1526-9523(02)00330-6.
193. Mislin GL, Schalk IJ (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6:408-420. doi:10.1039/c3mt00359k.
194. Mital A (2009) Synthetic nitroimidazoles: biological activities and mutagenicity relationships. Sci Pharm 77:497-520. doi:10.3797/scipharm.0907-14.
195. Mizrahi V, Henrie RN, Marlier JF et al (1985) Rate-limiting steps in the DNA polymerase I reaction pathway. Biochemistry 24:4010-4018. doi:10.1021/bi00336a031.
196. Mohammadi T, Karczmarek A, Crouvoisier M et al (2007) The essential peptidoglycan glycosyltransferase MurG forms a complex with proteins involved in lateral envelope growth as well as with proteins involved in cell division in Escherichia coli. Mol Microbiol 65:1106-1121. doi:10.1111/j.1365-2958.2007.05851.x.
197. Mohammadi T, van Dam V, Sijbrandi R et al (2011) Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J 30:1425-1432. doi:10.1038/emboj.2011.61.
198. Moreno M, Elgaher WAM, Herrmann J et al (2015) Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp. Synlett 26:1175-1178. doi:10.1055/s-0034-1380509.
199. Morrison C (2015) Antibacterial antibodies gain traction. Nat Rev Drug Discov 14:737-738. doi:10.1038/nrd4770.
200. Mullane KM, Gorbach S (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 9:767-777. doi:10.1586/eri.11.53.
201. Münch D, Roemer T, Lee SH et al (2012) Identification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus. PLoS Pathog 8:1-11. doi:10.1371/journal.ppat.1002509.
202. Münch D, Engels I, Müller A et al (2015) Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother 59:772-781. doi:10.1128/AAC.02663-14.
203. Murai M, Kaji T, Kuranaga T et al (2015) Total synthesis and biological evaluation of the antibiotic lysocin E and its enantiomeric, epimeric, and N-demethylated analogues. Angew Chem Int Ed 54:1556-1560. doi:10.1002/anie.201410270.
204. Nesme J, Simonet P (2015) The soil resistome: a critical review on antibiotic resistance origins, ecology and dissemination potential in telluric bacteria. Environ Microbiol 17:913-930. doi:10.1111/1462-2920.12631.
205. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311-335. doi:10.1021/np200906s.
206. Nichols D, Cahoon N, Trakhtenberg EM et al (2010) Use of ichip for high-throughput in situ cultivation of "uncultivable" microbial species. Appl Environ Microbiol 76:2445-2450. doi:10.1128/AEM.01754-09.
207. Nicolau DP (2008) Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9:23-37. doi:10.1517/14656566.9.1.23.
208. Niiranen L, Lian K, Johnson KA, Moe E (2015) Crystal structure of the DNA polymerase III b subunit (b-clamp) from the extremophile Deinococcus radiodurans. BMC Struct Biol. doi:10.1186/s12900-015-0032-6.
209. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593-656. doi:10.1128/MMBR.67.4.593.
210. Nöllmann M, Crisona NJ, Arimondo PB (2007) Thirty years of Escherichia coli DNA gyrase: From in vivo function to single-molecule mechanism. Biochimie 89:490-499. doi:10.1016/j.biochi.2007.02.012.
211. Noufflard-Guy-Loé H, Berteaux S (1965) Rev Tuberc Pneumol 29:301-326.
212. Novak R (2011) Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci 1241:71-81. doi:10.1111/j.1749-6632.2011.06219.x.
213. Nowicka B, Kruk J (2010) Occurrence, biosynthesis and function of isoprenoid quinones. Biochim Biophys Acta Bioenerg 1797:1587-1605. doi:10.1016/j.bbabio.2010.06.007.
214. O’Connell KMG, Hodgkinson JT, Sore HF et al (2013) Combating multidrug-resistant bacteria: Current strategies for the discovery of novel antibacterials. Angew Chem Int Ed 52:10706-10733. doi:10.1002/anie.201209979.
215. O’Neill J (2015) Securing new drugs for future generations: the pipeline of antibiotics. Wellcome Trust, London.
216. Oakley AJ, Prosselkov P, Wijffels G et al (2003) Flexibility revealed by the 1.85 Å crystal structure of the b sliding-clamp subunit of Escherichia coli DNA polymerase III. Acta Crystallogr Sect D 59:1192-1199. doi:10.1107/S0907444903009958.
217. Oliphant CM, Green GM (2002) Quinolones: a comprehensive review. Am Fam Physician 65:455-464.
218. Opperman TJ, Nguyen ST (2015) Recent advances toward a molecular mechanism of efflux pump inhibition. Front Microbiol 6:1-16. doi:10.3389/fmicb.2015.00421.
219. Ozawa K, Horan NP, Robinson A et al (2013) Proofreading exonuclease on a tether: the complex between the E. coli DNA polymerase III subunits a, e, h and b reveals a highly flexible arrangement of the proofreading domain. Nucleic Acids Res 41:5354-5367. doi:10.1093/nar/gkt162.
220. Page MGP (2013) Siderophore conjugates. Ann N Y Acad Sci 1277:115-126. doi:10.1111/nyas.12024.
221. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011) Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943-4960. doi:10.1128/AAC.00296-11.
222. Paris L (2015) Report of the Antibiotics resistance project: antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibioticscurrently-in-clinical-development.
223. Parmar A, Iyer A, Vincent CS et al (2016) Efficient total syntheses and biological activities of two teixobactin analogues. Chem Commun 52:6060-6063. doi:10.1039/C5CC10249A.
224. Payne DJ, Gwynn MN, Holms DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challanges of antibacterial discovery. Nat Rev Drug Discov 6:29-40.
225. Pelchovich G, Omer-Bendori S, Gophna U (2013) Menaquinone and iron are essential for complex colony development in Bacillus subtilis. PLoS ONE 8:1-14. doi:10.1371/journal.pone.0079488.
226. Pendleton JN, Gorman SP, Gilmore BF (2013) Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297-308. doi:10.1586/eri.13.12.
227. Pereira MP, Schertzer JW, D’Elia MA et al (2008) The wall teichoic acid polymerase TagF efficiently synthesizes poly(glycerol phosphate) on the TagB product lipid III. ChemBioChem 9:1385-1390. doi:10.1002/cbic.200800026.
228. Perez-Cruz C, Delgado L, Lopez-Iglesias C, Mercade E (2015) Outer-inner membrane vesicles naturally secreted by gram-negative pathogenic bacteria. PLoS ONE 10:1-18. doi:10.1371/journal.pone.0116896.
229. Perry JA, Westman EL, Wright GD (2014) The antibiotic resistome: what’ s new? Curr Opin Microbiol 21:45-50. doi:10.1016/j.mib.2014.09.002.
230. Peterson LR (2009) Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 49:992-993. doi:10.1086/605540.
231. Piddock LJV (2012) The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis 12:249-253. doi:10.1016/S1473-3099(11)70316-4.
232. Piddock LJV (2015) Teixobactin, the first of a new class of antibiotics discovered by ichip technology? J Antimicrob Chemother 70:2679-2680. doi:10.1093/jac/dkv175.
233. Piel J (2010) Biosynthesis of polyketides by trans-AT polyketide synthases. Nat Prod Rep 27:9961047. doi:10.1039/b816430b.
234. Pinho MG, Errington J (2005) Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates. Mol Microbiol 55:799-807. doi:10.1111/j.1365-2958.2004.04420.x.
235. Pinho MG, de Lencastre H, Tomasz A (2001) An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci USA 98:10886-10891. doi:10.1073/pnas.191260798.
236. Policy IP (2010) The 10 ‘20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081-1083. doi:10.1086/652237.
237. Polz MF, Alm EJ, Hanage WP (2013) Horizontal gene transfer and the evolution of bacterial and archaeal population structure. Trends Genet 29:170-175. doi:10.1016/j.tig.2012.12.006.
238. Powers JH (2003) Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis 16:547-551. doi:10.1097/01.qco.0000104294.87920.b4.
239. Projan SJ (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6:427-430. doi:10.1016/j.mib.2003.08.003.
240. Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792-821. doi:10.1128/CMR.00033-13.
241. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117-128. doi:10.1038/nrd3013.
242. Rawat D, Nair D (2010) Extended-spectrum beta-lactamases in gram negative bacteria. J Glob Infect Dis 2:263-274. doi:10.4103/0974-777X.68531.
243. Reck F, Alm RA, Brassil P et al (2012) Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: antibacterial agents with an improved safety profile. J Med Chem 55:6916-6933. doi:10.1021/jm300690s.
244. Redgrave LS, Sutton SB, Webber MA, Piddock LJV (2014) Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22:438-445. doi:10.1016/j.tim.2014.04.007.
245. Rex JH (2014) ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12:231-232. doi:10.1038/nrmicro3245.
246. Robinson A, Causer RJ, Dixon NE (2012) Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr Drug Targets 13:352-372. doi:10.2174/138945012799424598.
247. Roca J, Wang JC (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840. doi:10.1016/0092-8674(92)90558-T.
248. Roca J, Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77:609-616. doi:10.1016/0092-8674(94)90222-4.
249. Roca J, Berger JM, Harrison SC, Wang JC (1996) DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Proc Natl Acad Sci U S A 93:4057-4062. doi:10.1073/pnas.93.9.4057.
250. Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Blázquez J (2013) Antibiotics and antibiotic resistance: A bitter fight against evolution. Int J Med Microbiol 303:293-297. doi:10.1016/j.ijmm.2013.02.004.
251. Royer M, Costet L, Vivien E et al (2004) Albicidin pathotoxin produced by Xanthomonas albilineans is encoded by three large PKS and NRPS genes present in a gene cluster also containing several putative modifying, regulatory, and resistance genes. Mol Plant Microbe Interact 17:414-427.
252. Saha R, Saha N, Donofrio RS, Bestervelt LL (2013) Microbial siderophores: a mini review. J Basic Microbiol 53:303-317. doi:10.1002/jobm.201100552.
253. Sanchez S, Demain AL (eds) (2015) Antibiotics: current innovations and future trends. Caister Academic Press, Norfolk.
254. Sauvage E, Kerff F, Terrak M et al (2008) The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 32:234-258. doi:10.1111/j.1574-6976.2008.00105.x.
255. Savoia D (2012) Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiol 7:979-990. doi:10.2217/fmb.12.68.
256. Schäberle TF, Lohr F, Schmitz A, König GM (2014) Antibiotics from myxobacteria. Nat Prod Rep 31:953. doi:10.1039/c4np00011k.
257. Schaefer B (2014) Natural Products in the Chemical Industry. Springer, Berlin & Heidelberg.
258. Schoeffler AJ, Berger JM (2008) DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 41:41-101. doi:10.1017/S003358350800468X.
259. Schoepp-Cothenet B, Lieutaud C, Baymann F et al (2009) Menaquinone as pool quinone in a purple bacterium. Proc Natl Acad Sci U S A 106:8549-8554. doi:10.1073/pnas.0813173106.
260. Schueffler A, Anke T (2014) Fungal natural products in research and development. Nat Prod Rep 1425-1448. doi:10.1039/C4NP00060A.
261. Schwartz B, Markwalder JA, Wang Y (2001) Lipid II: total synthesis of the bacterial cell wall precursor and utilization as a substrate for glycosyltransfer and transpeptidation by penicillin binding protein (PBP) 1b of Eschericia coli. J Am Chem Soc 123:11638-11643. doi:10.1021/ja0166848.
262. Schwechheimer C, Kuehn MJ (2015) Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol 13:605-619. doi:10.1038/nrmicro3525.
263. Scott LJ (2013) Fidaxomicin: a review of its use in patients with clostridium difficile infection. Drugs 73:1733-1747. doi:10.1007/s40265-013-0134-z.
264. Scott CP, Abel-Santos E, Wall M et al (1999) Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A 96:13638-13643. doi:10.1073/pnas.96.24.13638.
265. Sewell EWC, Brown ED (2014) Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics. J Antibiot 67:43-51. doi:10.1038/ja.2013.100.
266. Shahul HP, Solapure S, Mukherjee K et al (2014) Optimization of pyrrolamides as mycobacterial gyrb atpase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother 58:61-70. doi:10.1128/AAC.01751-13.
267. Sham L-T, Butler EK, Lebar MD et al (2014) MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science 345:220-222.
268. Sharma M, Chauhan PM (2012) Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges. Future Med Chem 4:1335-1365. doi:10.4155/fmc.12.68.
269. Shiva F (2015) Antibiotic prescription and bacterial resistance. Arch Pediatr Infect Dis 3:e21540. doi:10.5812/pedinfect.21540.
270. Silver LL (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6:41-55. doi:10.1038/nrd2202.
271. Singh GS (2004) b-Lactams in the new millennium. Part-I: monobactams and carbapenems. Med Chem (Los Angeles) 4:62-92.
272. Smillie C, Garcillan-Barcia MP, Francia MV et al (2010) Mobility of plasmids. Microbiol Mol Biol Rev 74:434-452. doi:10.1128/MMBR.00020-10.
273. Spellberg B, Powers JH, Brass EP et al (2004) Trends in antimicrobial drug development: implications for the future 90502:1279-1286.
274. Stadler M, Hoffmeister D (2015) Fungal natural products-the mushroom perspective. Front Microbiol 6:1-4. doi:10.3389/fmicb.2015.00127.
275. Storm DR, Strominger JL (1974) Binding of bacitracin to cells and protoplasts of Micrococcus lysodeikticus. J Biol Chem 249:1823-1827.
276. Stukenberg PT, Studwell-Vaughan PS, O’Donnell M, O’Donnell M (1991) Mechanism of the sliding beta-clamp of DNA polymerase III holoenzyme. J Biol Chem 266:11328-11334. doi:10.1074/jbc.M111.338145.
277. Su X-H, Wang B-X, Le W-J et al (2016) Multidrug-resistant neisseria gonorrhoeae Isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother 60:621-623. doi:10.1128/AAC.01211-15.
278. Swoboda JG, Meredith TC, Cambell J et al (2010) Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Stphylococcus aureus. ACS Chem Biol 5:839-849.
279. Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S (2011) Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosynthesis in Staphylococcus aureus. ACS Chem Biol 6:106-116.
280. Syvanen M (2012) Evolutionary implications of horizontal gene transfer. Annu Rev Genet 46:341-358. doi:10.1146/annurev-genet-110711-155529.
281. Tari LW, Li X, Trzoss M et al (2013) Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. PLoS ONE 8:e84409. doi:10.1371/journal.pone.0084409.
282. Taubes G (2008) The bacterial fight back. Science 321:356-361.
283. Tegos GP, Haynes M, Strouse JJ et al (2011) Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des 17:1291-1302. doi:10.1038/nature11130.
284. Reduced Terlain B, Thomas JP (1969) C R Hebd Seances Acad Sci Ser C 269:1546-1549.
285. Terlain B, Thomas JP (1971a) Bull Chim Soc Fr 6:2349-2356.
286. Terlain B, Thomas JP (1971b) Bull Chim Soc Fr 6:2357-2362.
287. Tettelin H, Riley D, Cattuto C, Medini D (2008) Comparative genomics: the bacterial pan-genome. Curr Opin Microbiol 11:472-477. doi:10.1016/j.mib.2008.09.006.
288. ’tHart P, Oppedijk SF, Breukink E, Martin NI (2016) New insights into nisin’s antibacterial mechanism revealed by binding studies with synthetic lipid II analogues. Biochemistry 55:232-237. doi:10.1021/acs.biochem.5b01173.
289. Thaker M, Spanogiannopoulos P, Wright GD (2010) The tetracycline resistome. Cell Mol Life Sci 67:419-431. doi:10.1007/s00018-009-0172-6.
290. Tommasi R, Brown DG, Walkup GK et al (2015) ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14:529-542. doi:10.1038/nrd4572.
291. Torres C (2010) Up against the wall. Nat Med 16:628-631. doi:10.1038/nm0610-628.
292. Toussaint KA, Gallagher JC (2015) b-Lactam/b-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86-98. doi:10.1177/1060028014556652.
293. Upadhyay A, Upadhyaya I, Kollanoor-Johny A, Venkitanarayanan K (2014) Combating pathogenic microorganisms using plant-derived antimicrobials: a minireview of the mechanistic basis. Biomed Res Int. doi:10.1155/2014/761741.
294. Uria-Nickelsen M, Neckermann G, Sriram S et al (2013) Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines. Int J Antimicrob Agents 41:363-371. doi:10.1016/j.ijantimicag.2012.12.001.
295. Venter H, Mowla R, Ohene-Agyei T, Ma S (2015) RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 6:377. doi:10.3389/fmicb.2015.00377.
296. Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. P & T 40:277-283.
297. Vivien E, Pitorre D, Cociancich S et al (2007) Heterologous production of albicidin: a promising approach to overproducing and characterizing this potent inhibitor of DNA gyrase. Antimicrob Agents Chemother 51:1549-1552. doi:10.1128/AAC.01450-06.
298. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440. doi:10.1038/nrm831.
299. Wang H, Gill CJ, Lee SH et al (2013) Discovery of wall teichoic acid inhibitors as potential anti-MRSA beta-lactam combination agents. Chem Biol 20:272-284. doi:10.1016/j.chembiol.2012.11.013.
300. Wang W, Qiu Z, Tan H, Cao L (2014) Siderophore production by actinobacteria. Biometals 27:623-631. doi:10.1007/s10534-014-9739-2.
301. Watanakunakorn C (1984) Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 14:7-18. doi:10.1093/jac/14.suppl_D.7.
302. Wattal C, Goel N (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9:894-896. doi:10.1038/nrmicro2693.
303. Whitman WB, Coleman DC, Wiebe WJ (1998) Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 95:6578-6583. doi:10.1073/pnas.95.12.6578.
304. Wiedemann I, Breukink E, Van Kraaij C et al (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772-1779. doi:10.1074/jbc.M006770200.
305. Wijffels G, Dalrymple BP, Prosselkov P et al (2004) Inhibition of protein interactions with the beta 2 sliding clamp of Escherichia coli DNA polymerase III by peptides from beta 2-binding proteins. Biochemistry 43:5661-5671. doi:10.1021/bi036229j.
306. Wijffels G, Johnson WM, Oakley AJ et al (2011) Binding inhibitors of the bacterial sliding clamp by design. J Med Chem 54:4831-4838. doi:10.1021/jm2004333.
307. Williams DH, Bardsley B (1999) The vancomycin group of antibiotics and the fight against resistant bacteria. Angew Chem Int Ed 38:1172-1193. doi:10.1002/(SICI)1521-3773(19990503)38:9<1172:AID-ANIE1172>3.0.CO;2-C.
308. Wolff P, Amal I, Olieric V et al (2014) Differential modes of peptide binding onto replicative sliding clamps from various bacterial origins. J Med Chem 57:7565-7576. doi:10.1021/jm500467a.
309. Wright GD (2007) The antibiotic resistome: the nexus of chemical and genetic diversity. NatRevMicrobiol 5:175-186. doi:10.1038/nrmicro1614.
310. Wright GD (2010) The antibiotic resistome. Exp Opin Drug Disc 5:779-788. doi:10.1517/17460441.2010.497535.
311. Wright GD (2012) The origins of antibiotic resistance. In: Coates ARM (ed) Handbook of experimental pharmacology, pp 45-65.
312. Wright G (2015a) An irresistible newcomer. Nature 517:442-443. doi:10.1038/nature14193.
313. Wright GD (2015b) Solving the antibiotic crisis. ACS Infect Dis 1:80-84. doi:10.1021/id500052s.
314. Wright GD, Poinar H (2012) Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol 20:157-159. doi:10.1016/j.tim.2012.01.002.
315. Wright PM, Seiple IB, Myers AG (2014) The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed 53:8840-8869. doi:10.1002/anie.201310843.
316. Wyke AW, Ward JB, Hayes MV, Curtis NAC (1981) A role in vivo for penicillin-binding protein-4 of Staphylococcus aureus. Eur J Biochem 119:389-393. doi:10.1111/j.1432-1033.1981.tb05620.x.
317. Xu Z-Q, Flavin MT, Flavin J (2014a) Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs 23:163-182. doi:10.1517/13543784.2014.848853.
318. Xu Z-Q, Flavin MT, Flavin J (2014b) Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs 23:163-182. doi:10.1517/13543784.2014.848853.
319. Yahav D, Farbman L, Leibovici L, Paul M (2011) Colistin: new lessons on an old antibiotic: EBSCOhost. Clin Microbiol Infect 18:18-29.
320. Yin Z, Wang Y, Whittell LR et al (2014a) DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 21:481-487. doi:10.1016/j.chembiol.2014.02.009.
321. Yin Z, Whittell LR, Wang Y et al (2014b) Discovery of lead compounds targeting the bacterial sliding clamp using a fragment-based approach. J Med Chem 57:2799-2806. doi:10.1021/jm500122r.
322. Yin Z, Whittell LR, Wang Y et al (2015) Bacterial sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous linear motifs. J Med Chem 58:4693-4702. doi:10.1021/acs.jmedchem.5b00232.
323. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271-1272. doi:10.1128/aac.34.6.1271.
324. Yoshida H, Bogaki M, Nakamura M et al (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647-1650. doi:10.1128/AAC.35.8.1647.
325. Young IG (1975) Biosynthesis of bacterial menaquinones. Menaquinone mutants of Escherichia coli. Biochemistry 14:399-406. doi:10.1021/bi00673a029.
326. Yunis AA (1988) Chloramphenicol: relation of structure to activity and toxicity. Annu Rev Pharmacol Toxicol 28:83-100 doi:10.1146/annurev.pa.28.040188.000503.
327. Zaffiri L, Gardner J, Toledo-Pereyra LH (2012) History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 25:67-77. doi:10.3109/08941939.2012.664099.
328. Zapun A, Philippe J, Abrahams KA et al (2013) In vitro reconstitution of peptidoglycan assembly from the gram-positive pathogen streptococcus pneumoniae. ACS Chem Biol 8:2688-2696. doi:10.1021/cb400575t.
329. Zetts R (2014) Report of the Antibiotics resistance project: antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development.
330. Zgurskaya HI, López CA, Gnanakaran S (2015) Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis 1:512-522. doi:10.1021/acsinfecdis.5b00097.
331. Zhanel GG, Walkty AJ, Karlowsky JA (2015) Fidaxomicin: a novel agent for the treatment of clostridium difficile infection. Can J Infect Dis Med Microbiol 26:305-313.
332. Zhang G, Meredith TC, Kahne D (2013) On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr Opin Microbiol 16:779-785. doi:10.1016/j.mib.2013.09.007.
333. Zhao M, Goedecke T, Gunn J, et al (2013) Protostane and fusidane triterpenes: a mini-review. Molecules 18:4054-4080. doi:10.3390/molecules18044054.